Oral isotretinoin is the most effective treatment option used in acne treatment. However, varying rates of relapse have been reported after oral isotretinoin therapy. The aim of this study was to evaluate factors that affect relapse after oral isotretinoin treatment in patients with acne. In this cross-sectional study, 212 patients with acne using 0.3-1 mg/kg/day oral isotretinoin for at least 4 months were analyzed retrospectively regarding relapse frequency and factors that affected relapse. In the study, the female-to-male ratio was 3.15, with a mean age of 23.5 ± 6.2 years. The relapse rate was found as 37.3%. The median time to relapse was 10 months. The relapse rate was higher in younger patients (age ≤ 20 years), macrocomedone-type acne, and those with residual lesions at the end of the treatment (p < 0.05 and p < 0.01, respectively). To prevent relapse in patients with acne using oral isotretinoin, it is of great importance to continue the treatment until complete clinical improvement, and extend the treatment for at least one more month regardless of the cumulative dose. Relapse may also occur with younger age and macrocomedone-type acne.

Background Cutaneous side effects are commonly seen in cancer chemotherapy. As new chemotherapy drugs are developed, the frequency and the diversity of these cutaneous side effects increase. For this reason, identification and management of these side effects are an important part of the treatment of cancer patients. This study aimed to investigate mucocutaneous side effects of conventional chemotherapy and targeted therapy agents that are used in cancer patients. MethodsIn this cross-sectional study, 231 cancer patients, who received single or combination chemotherapy at the oncology department of our hospital between 2013 and 2020, were retrospectively reviewed, and mucocutaneous side effects we evaluated. ResultsThe ages of the patients varied between 27 and 90 years with a median age of 60 years. Of the patients, 136 (58.9%) were women, and 95 (41.1%) were men.Combination chemotherapy was applied to 174 patients (71.9%). A total of 558 mucocutaneous side effects were present in 231 patients. The most common side effect was alopecia, which was observed in 158 patients (65.6%). This was followed by mucositis (39.4%), hand-foot syndrome (35.3%), papulopustular rash (22%), dermatitis (18.3%), xerosis (14.1%), nail disorders (12%), and others.Conclusions Although chemotherapy-induced cutaneous side effects are not usually lifethreatening, they may lead to the development of morbidity and discontinuance or termination of the treatment. Therefore, these side effects should be well managed to improve the quality of life of cancer patients.

Oral isotretinoin is an effective treatment for severe acne. However, psychiatric side effects are noted, including a few cases of psychosis and mania triggered by isotretinoin. In this report, we present a case of visual hallucinations due to isotretinoin. In our case, with the discontinuation of isotretinoin, the hallucinations regressed and no other cause was found.

No abstract

Bexarotene 1% gel is an effective and generally well-tolerated treatment option for early stage cutaneous T cell lymphoma (CTCL) patients who are resistant or intolerant to other topical therapies, with less than 15% body surface area involvement. 1 Folliculotropic mycosis fungoides (FMF) is the most common subtype of MF and is characterized by hairless, indurated, scaly, erythematous patches, plaques, or tumors that preferentially involve the head, neck, and eyebrow.A 47-year-old male patient with a one-month history of hair loss